U.S. State Department Reverts to Times New Roman in Push for “Professionalism” 
Special Prosecutor Alleges Yoon Suk Yeol Sought North Korea Provocation to Justify Martial Law 
DOJ Sues Loudoun County School Board Over Transgender Locker Room Policy 
Syria Arrests Five Suspects After Deadly Attack on U.S. and Syrian Troops in Palmyra 
U.S. Military Bill Seeks to End Dependence on China for Display Technology by 2030 
U.S. and Mexico Reach New Agreement to Tackle Tijuana River Sewage Crisis 
Jimmy Lai Convicted Under Hong Kong National Security Law in Landmark Case 
Australia’s Under-16 Social Media Ban Sparks Global Debate and Early Challenges 
Trump Signs Executive Order to Establish National AI Regulation Standard 
European Leaders Tie Ukraine Territorial Decisions to Strong Security Guarantees 
Trump’s Approval of AI Chip Sales to China Triggers Bipartisan National Security Concerns 
Ukraine’s NATO Concession Unlikely to Shift Peace Talks, Experts Say 
Trump Administration Moves to Keep TransAlta Coal Plant Running Amid Rising AI Power Demand 
China Adds Domestic AI Chips to Government Procurement List as U.S. Considers Easing Nvidia Export Curbs 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
EU Expands Carbon Border Levy to Car Parts and Appliances, Tightening Climate Trade Rules 
Australia Pushes Forward on AUKUS Submarine Program Amid Workforce and Production Challenges 
A bipartisan group of U.S. lawmakers has urged the Biden administration to consider restricting biotechnology exports to China’s military, citing concerns over potential weaponization to create toxic pathogens. In a letter to Commerce Secretary Gina Raimondo, lawmakers, led by Republican China Select Committee Chairman John Moolenaar and Democrat Raja Krishnamoorthi, called for licensing restrictions on U.S. pharmaceutical companies collaborating with Chinese military-owned medical entities.
The letter, reported by Reuters, highlights the national security risks of U.S.-China biotech competition, emphasizing the potential threat to healthcare advancements and American medical data security. Chinese Embassy spokesperson Liu Pengyu dismissed the claims as "malicious speculation," reiterating Beijing’s opposition to biological weapons.
Concerns about China’s biotechnology activities have grown among U.S. officials. In August, lawmakers, including Democrat Anna Eshoo, urged the FDA to increase scrutiny of U.S. clinical trials in China, citing risks of intellectual property theft and forced participation of Uyghurs in Xinjiang. U.S. pharmaceutical companies have reportedly collaborated with Chinese military-run hospitals on hundreds of clinical trials in the past decade.
In a January response, FDA Acting Associate Commissioner Laura Paulos assured lawmakers of strict protections for trial participants, stating that legally effective, informed consent is required. On intellectual property theft concerns, she deferred the matter to other federal agencies.
Commerce Secretary Raimondo’s upcoming departure could limit immediate action on new controls. However, the letter underscores growing bipartisan concern over China’s role in biotechnology and its implications for global security.
This development reflects broader efforts to address the strategic challenges posed by China across various industries, including biotechnology and healthcare.
